Erectile Dysfunction and Cardiovascular Disease. ED and Cardiovascular Diseases.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

Karam Paul MS, MD, MBA, FACC Community Heart and Vascular.
PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Ranexa™ for Chronic Angina An Unmet Need
MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE FEBRUARY 10,2110.
Silent ischemia W. William Heberden’s described in the 1770s of a new syndrome, centering around pain in the left chest and named by him “angina pectoris”.
Can we prevent stent restenosis after coronary stent implantation
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.
Ischemic Heart Disease.  Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (
Ischemic Heart Diseases IHD
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.
Update on the Medical Management of Acute Coronary Syndrome.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Procoralan plus beta-blockers as first-step therapy in heart failure?
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
Exercise Echocardiography Cardiac Issues 2011 Douglass A Morrison, MD, PhD.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
Myocardial Ischemia Redefined: Optimal Care in CAD.
New guidelines for CABG
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported.
Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.
Requirements from regulatory agencies: endpoints, comparators, type of studies.
Agents that Dilate Coronary Blood Vessels.  Coronary artery disease (CAD) results from atherosclerosis  Clinical symptoms caused by  narrowing of the.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Silent Ischemia STABLE CAD
Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.
Risk Stratification In Patients With Chronic Myocardial Ischemia.
Statistics: Unlocking the Power of Data Lock 5 STAT 250 Dr. Kari Lock Morgan Collecting Data: Randomized Experiments SECTION 1.3 Control/comparison group.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.
Effects of Ranolazine: from Angina to Cardiac Performance Iacopo Olivotto, MD Referral Center for Cardiomyopathies Careggi University Hospital Florence,
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Contemporary Management of Myocardial Ischemia
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.
Many alternatives for treating ischemia and angina: how to choose?
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does acute improvement of endothelial dysfunction.
Screening for CAD Nuclear Medicine prospective S.R.Zakavi,MD,IBNM Nuclear Medicine Research Center Mashhad University of Medical Sciences.
Indication Contraindication Preparation
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Ischaemic Heart Disease Acute Coronary Syndrome
The Anglo Scandinavian Cardiac Outcomes Trial
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
The percentage of subjects with de novo development of renal function impairment (GFR
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Insulin Secretagogues: Sulfonylureas and “Glinides”
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Ranolazine in Microvascular Dysfunction
The American College of Cardiology Presented by Dr. Timothy Henry
Drugs Used to Treat Angina Pectoris
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Erectile Dysfunction and Cardiovascular Disease

ED and Cardiovascular Diseases

Malattie cardiovascolari e disfunzione erettile Alterazione vascolare Aterosclerosi diffusa, ostruzione al flusso ematico Produzione di EDRF Peptidi vasoattivi Sindrome dismetabolica Terapia farmacologica Psicologica

DiureticiFrequente Beta-bloccantiFrequente Ca- antagonisti VerapamilFrequente DiltiazemFrequente AmlodipinaFrequente ACE-InibitoriFrequente ATII antagonistiRaro Alfa-liticiPotenziamento erezione Malattie cardiovascolari e disfunzione erettile Effetto della terapia farmacologica

Study Design Run in 3 months Atenolol - know side effects Atenolol - do not know side effects Atenolol - do not know drug Sildenafil Placebo Sildenafil Placebo Sildenafil Placebo QOL Questionnaire Report of ED Silvestri et al. In Press Eur Heart J 2003

Beta-blockers and Report of ED P<0.05 P<0.01 Comparisons vs pts blinded on treatment drug Silvestri et al. In Press Eur Heart J 2003

Effect of Sildenafil Citrate and Placebo in Patients Reporting ED Silvestri et al. In Press Eur Heart J 2003

Incidence of Cardiovascular Disease in Patients Referred for ED Study Objective  Evaluate cardiovascular risk and incidence of cardiovascular disease in cardiac asymptomatic patients with ED Study esign  Indication of exercise ECG and eventually to coronary angiography to 50 cardiac asymptomatic patients with suspected vasculogenic ED Pritzker MR. Circulation. 1999; 100 (suppl 1): I-711. Abstract 3751

Cardiovascular Disease in Patients with ED Pritzker MR. Circulation. 1999; 100 (suppl 1): I-711. Abstract 3751  In 40 patients out of 50 (80%) there was presence of multiple risk factors for CAD  Family history(n=32)  cigarette smoking(n=40)  total cholesterol >200 mg/dl(n=35)  HDL-c <40 mg/dl(n=18)  Hypertension(n=24)  Sedentary life style(n=38)  diabetes(n=10)  Exercise ECG was positivein 28/50 pazients  Coronary angiography was performed in 20 patients and showed  proximal LAD or 3vd in 6 pts  2 vd in 7  Single vessel disease in 7 pts

ED and Cardiovascular Disease Pritzker MR. Circulation. 1999; 100 (suppl 1): I-711. Abstract 3751  Asymptomatic patients with vasculogenic ED have a high incidence of CAD and high prevalence of CAD risk factors  but only a minority undergoes cardiovascular screening  Screening for cardiovascular disease in patients with vasculogenic ED may help to identify patients at high risk of cardiovascular events

Acute Ischemic Syndromes Severe Heart Failure (NYHA IV) Severe malignant effort-induced tachy- arrhythmia Cardiac Contraindications to Sexual Activity ACC/AHA Clinical Statement

Myocardial Ischemia During Sexual Activity in Patients with CAD Drory et al Am J Cardiol 1995 All Patients with myocardial ischemia during sexual activity had also ischemia on Holter ECG monitoring

In 19 pts with CAD during sexual activity ß-blockers completely abolished ECG changes and symptoms Drory et al Am J Cardiol 1995 Myocardial Ischemia During Sexual Activity in Patients with CAD

Sildenafil Use and Myocardial Ischemia in Patients with CAD Exercise tolerance Ischemic treashold Effect of Sildenafil on Myocardial Ischemia Effect of Sildenafil on Myocardial Ischemia in patients with CAD on therapy

Chronic use of nitrats has no beneficial efect upon cardiovasular mortality and morbidity and therefore can be easily changed with other drugs for the treatment of CAD in those patients requiring Sildenafil Acute nitrate administration must be always performed under medical supervision and the dose must be adjusted according to the degree of peripheral vasodilation Use of Sildenafil in Patients with CAD Using NItrates

** Effect of Sildenafil in Patients with CAD treated with ß-blockers Patrizi R. et al. It Heart J 2001

** Effect of Sildenafil in Patients with CAD treated with ß-blockers Patrizi R. et al. It Heart J 2001

Effects on Primary/Secondary End Points *P< PlaceboSildenafil Time to limiting angina Time to angina Time to 1 mm ST-segment depression Exercise duration % change from baseline * * * Fox KM et al Circulation 2001, abstract supplement

Trimetazidine and Nitrates on Total Ischemic Burden P=0.07 between treatments Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine and Nitrates on Ischemic Episodes During Sexual Activity P<0.04 Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine vs Nitrates on the Control of Anginal Episodes p<0.01 vs baseline p=0.048 vs nistrates p<0.01 vs baseline p<0.04 vs nistrates p<0.01 vs baseline Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine plus Sildenafil vs Nitrates Positive Exercise Tests p<0.01p<0.05 Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine plus Sildenafil vs Nitrates Heart Rate and Blood Pressure Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine plus Sildenafil or Nitrates on Exercise Test Parameters P<0.01 for all comparisons TMZ+S vs Baseline P<0.05 for all comparisons TMZ+S vs Nitrates+P Rosano et al Eur Heart J 2003 (abstr)

Trimetazidine plus Sildenafil or Nitrates on ST segment Depression P=0.048

Conclusions Sildenafil has positive effect on cardiac haemodynamics and increase coronary blood flow The effect of Sildenafil on blood pressure is minimal Sildenafil has a positive effect on exercise-induced myocardial ischemia in patients with CAD The use of sildenafil in patients with myocardial ischemia well controlled by anti-anginal drugs is safe